Introduction In Europe, poly(ADP-ribose) polymerase inhibitor (PARPi) approvals for advanced ovarian cancer (aOC) are for biomarker-specific patient populations. It is not known how these treatment label variations are reflected in real-world PARPi use. This real-world study describes clinical and tumor characteristics of patients with aOC who received a PARPi-containing first-line maintenance (1LM) treatment in France, Germany, and Italy.

Methods In this ongoing, multicenter, retrospective study, patients with epithelial aOC who initiated PARPi-containing 1LM treatment (01Oct2018 to 31Mar2023) were included. Characteristics at 1LM treatment initiation were described overall and separately for those who received niraparib monotherapy or olaparib-bevacizumab. Characteristics are presented for all countries, but treatment and biomarker testing data are pending for Germany.

Results Among 580 patients (Italy, 307; France, 141; Germany, 132), median age was 61 years (IQR, 53–70), 93.6% had high-grade serous tumors, 70.3% had stage III disease, and 87.2% had an ECOG PS score of 0–1. Among patients in France and Italy (table 1), 167 received niraparib monotherapy, and 82 received olaparib-bevacizumab. All patients underwent BRCA testing, but more homologous recombination deficiency (HRD) testing was conducted for patients receiving olaparib-bevacizumab (73.2%) than niraparib (20.4%). Of patients who received niraparib, 98.8% were BRCAwt. Of patients who received olaparib-bevacizumab, 95.1% were BRCA-mutated or BRCAwt and homologous recombination deficient.

Conclusion/Implications Among patients with aOC, the 1LM treatment patients received differed by HRD testing and biomarker status. Given the established prognostic value of BRCA/HRD status, these results emphasize the importance of considering biomarker status when evaluating real-world outcomes across 1LM treatment regimens.